Abstract
It sounded reasonable to many — patients can be started on buprenorphine without seeing a physician first, but must see that physician within 30 days. “Aren't people supposed to see their doctors anymore?” one Washington insider asked ADAW. That was what the Drug Enforcement Administration (DEA) proposed last month (see https://onlinelibrary.wiley.com/doi/10.1002/adaw.33712). This is a diversion from what providers got used to during the public health emergency of COVID‐19, when telehealth rules were lenient, mainly in order to prevent transmission of the virus. Now, those leniencies are being viewed as having an additional benefit: To make it easier for patients to get treatment for opioid use disorder (OUD) and offer a chance to reduce overdoses and deaths.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
